On November 15, Gelonghui reported that Wuxi Apptec (603259.SH) announced that its wholly-owned subsidiary WuXiPharmaTechHealthcareFundIL.P. (referred to as "WuXiFundI") signed a Subscription Agreement (referred to as "subscription agreement") with SofinnovaCapitalXIGPS.àr.l. (referred to as "general partner"), agreeing that WuXiFundI would subscribe for shares in SofinnovaCapitalXISCSpSICAV-RAIF (referred to as "investment fund") amounting to 10 million euros, accounting for approximately 4.40% of the total raised investment fund shares (the proportion of investment fund shares held by WuXiFundI will be further diluted with the increase in subsequent fundraising amounts of the investment fund). As of the date of this announcement, WuXiFundI has not yet paid the investment amount, and WuXiFundI will fulfill its obligation to pay the investment amount with its own funds in accordance with the requirements of the subscription agreement. The investment fund mainly focuses on investing in startups in the life sciences field globally (especially in the biomedical and medical instruments industry). Approximately 70% of the fund's investments are directed towards startups in Europe, while about 30% is allocated for investments outside of Europe.

Sofinnova Partners is a well-known biotechnology investment institution in Europe, with over 50 years of industry experience and an excellent investment record in the European life sciences sector. The investment fund focuses on making impactful investments in early-stage biomedical companies in Europe, aiming to transform high-quality research results into thriving early-stage biotechnology enterprises that are globally competitive. The fund manager has established a broad and trusted network of entrepreneurs and scientists, aligning closely with the company's strategic mission to empower the global development of biomedical science and promote scientific transformation.